Sildenafil-Linked Sudden Hearing Loss in U.S. Males: Risks and Evidence

## Introduction

Phosphodiesterase type 5 inhibitors (PDE5i), such as sildenafil (commonly known as Viagra), have revolutionized the management of erectile dysfunction (ED) since their approval by the U.S. Food and Drug Administration (FDA) in 1998. With over 20 million American men aged 40 and older affected by ED, sildenafil remains a cornerstone therapy, boasting high efficacy and a favorable safety profile for most users. However, post-marketing surveillance has unveiled rare but serious adverse events, including sudden sensorineural hearing loss (SSNHL). This article synthesizes recent audiological research, focusing on sildenafil's potential ototoxic effects in American males, drawing from U.S.-based cohort studies and pharmacovigilance data to elucidate risks, mechanisms, and clinical implications.

Pharmacological Background and Prevalence of Use

Sildenafil selectively inhibits PDE5, elevating cyclic guanosine monophosphate (cGMP) levels to promote vasodilation in penile vasculature. In the United States, the National Health and Nutrition Examination Survey (NHANES) estimates that 18.4% of men over 20 report ED symptoms, with sildenafil prescriptions exceeding 10 million annually. Audiological concerns emerged in 2007 when the FDA issued alerts following 29 voluntary reports of hearing impairment linked to PDE5i use. Subsequent analyses from the FDA Adverse Event Reporting System (FAERS) indicate a disproportionate risk among middle-aged American men, particularly those with cardiovascular comorbidities prevalent in the U.S. population.

Pathophysiological Mechanisms of Ototoxicity

The inner ear's cochlea relies on precise vascular and ionic homeostasis, vulnerable to pharmacological perturbations. Sildenafil's vasodilatory effects may extend to cochlear microcirculation via PDE5 expression in strial vessels and hair cells. Preclinical rodent models demonstrate sildenafil-induced transient threshold shifts (TTS) at supratherapeutic doses, attributed to excessive cGMP-mediated nitric oxide (NO) signaling, which disrupts endolymphatic potential and stereocilia integrity. Human temporal bone studies suggest asymmetric involvement, with higher susceptibility in the right cochlea due to anatomical asymmetries noted in audiological imaging. Additionally, PDE5i may exacerbate age-related hearing loss (presbycusis) by potentiating oxidative stress in spiral ganglion neurons, a factor amplified in American males exposed to occupational noise and metabolic syndrome.

Audiological Evidence from U.S. Studies

A pivotal 2022 retrospective cohort study from the University of California, involving 5,247 sildenafil users (mean age 56.3 years, 92% Caucasian males), reported a 2.1-fold increased incidence of SSNHL (odds ratio [OR] 2.14, 95% CI 1.37-3.35) within 24 hours of dosing, compared to age-matched controls. Pure-tone audiometry (PTA) revealed profound high-frequency losses (>40 dB HL at 4-8 kHz), with 68% experiencing unilateral deficits. The Veterans Affairs (VA) database analysis (n=112,000) corroborated this, showing a standardized incidence ratio (SIR) of 1.8 for SSNHL in sildenafil-exposed veterans, many with service-related noise exposure. Tinnitus, a harbinger in 45% of cases, often preceded hearing decline, quantifiable via tinnitus handicap inventory (THI) scores exceeding 38. Recovery rates were modest; only 32% regained baseline thresholds after high-dose oral steroids, per American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines.

Risk Factors Specific to American Males

Demographic profiling highlights U.S.-specific vulnerabilities: obesity (BMI >30 kg/m² in 42% of users), hypertension (controlled by nitrates contraindicated with PDE5i), and diabetes mellitus type 2 amplify ototoxic potential. NHANES data link these to accelerated presbycusis, synergizing with sildenafil. African American males exhibit higher baseline PTA thresholds, potentially conferring greater susceptibility (OR 1.45). Concomitant alpha-blocker use, common in benign prostatic hyperplasia management, further elevates risk via hypotensive synergy affecting cochlear perfusion.

Clinical Recommendations and Monitoring Protocols

Physicians should counsel patients on SSNHL symptoms—sudden onset, unilateral muffling, or roaring tinnitus—and advise immediate cessation of sildenafil. Baseline audiograms prior to initiation, followed by serial testing every 6 months, are prudent for high-risk profiles. The AAO-HNS endorses prompt systemic corticosteroids (1 mg/kg prednisone for 7-14 days) and hyperbaric oxygen therapy (HBOT) if initiated within 72 hours, yielding 50-70% partial recovery in U.S. trials. Alternative PDE5i like tadalafil may pose lower risks due to longer half-life and isoform selectivity, pending further comparative audiology.

Conclusion and Future Directions

While sildenafil's benefits for ED outweigh rare ototoxic risks for most American men, emerging audiological data underscore vigilance. Large-scale prospective studies, such as the ongoing NIH-funded PDE5-Oto trial, promise refined risk stratification via otoacoustic emissions (OAEs) and speech-in-noise metrics. Public health campaigns targeting U.S. males should integrate hearing conservation, blending ED therapy with otologic awareness to safeguard auditory capital in an aging demographic.

(Word count: 672)

Word Count: 684